Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 283-287, June 2010

Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal

Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India

Received 24 September 2009; received in revised form 6 April 2010; accepted 6 April 2010. published online 10 May 2010.

Abstract 

Purpose

To perform a systematic analysis of clinical data of presentation, treatment, outcome, toxicity, survival and other associated prognostic factors of the patients of anal canal who received treatment at our hospital.

Methods and materials

The medical records of 257 patients treated with radiotherapy with or without chemotherapy from the year 1985 to 2005 were studied.

Results

Median follow-up was 36months. Complete clinical response after radiotherapy was 74.4% in the whole group. The 5years overall (OAS) and disease-free (DFS) survival for the whole group was 71.5% and 61%, respectively. Patients with T1–2 tumors which received the radiation dose between 55 and 60Gy had superior locoregional control, DFS and OAS. Similarly T3–4 tumors receiving radiation dose more than 60Gy independently improved the locoregional control, DFS and OAS irrespective of the nodal status and addition of chemotherapy.

Conclusions

Radiation dose of 56–60Gy for T1 and T2 and 65Gy for T3 and T4 tumors along with concurrent chemotherapy is required to achieve better local control, disease-free survival and overall survival, with acceptable toxicity.

Keywords: Anal canal, Cancer, Prognostic factors, Radiation dose

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(10)00239-2

doi:10.1016/j.radonc.2010.04.013

Radiotherapy & Oncology
Volume 95, Issue 3 , Pages 283-287, June 2010